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Background Vascular modifications occur early in the development of psoriasis, and
angiogenesis is one of the key features in the pathogenesis of the disease.
Objectives To identify the role of the S100 protein psoriasin in psoriasis-associated
angiogenesis.
Methods The role of psoriasin in mediating angiogenesis was investigated by
silencing psoriasin with small interfering RNA (siRNA) and measuring psoriasis-
associated angiogenic factors in human epidermal keratinocytes. The secretion of
psoriasin and the effect of psoriasin on general regulators of angiogenesis in ker-
atinocytes, and on endothelial cell migration, proliferation, tube formation and
production of angiogenic mediators, was evaluated.
Results Reactive oxygen species (ROS) and hypoxia induced the expression of pso-
riasin. Downregulation of psoriasin in keratinocytes using siRNA altered the ROS-
induced expression of the psoriasis-associated angiogenic factors vascular
endothelial growth factor (VEGF), heparin-binding epidermal growth factor-like
growth factor, matrix metalloproteinase 1 and thrombospondin 1. Overexpres-
sion of psoriasin altered several regulators of angiogenesis and led to the secre-
tion of psoriasin. Treatment with extracellular psoriasin induced proliferation,
migration and tube formation in dermal-derived endothelial cells to a similar
extent as VEGF and interleukin-17, and induced the expression and release of
proangiogenic mediators. These effects were suggested to be mediated by the
PI3K and nuclear factor kappa B pathways.
Conclusions These findings suggest that psoriasin expression is promoted by oxida-
tive stress in keratinocytes and amplifies the ROS-induced expression of angio-
genic factors relevant to psoriasis. Moreover, extracellularly secreted psoriasin
may act on dermal endothelial cells to contribute to key features angiogenesis.
What’s already known about this topic?
• Psoriasis is characterized by extensive new blood vessel formation.
• Early microvascular modifications in the psoriatic lesion have received limited
attention in psoriasis pathogenesis.
What does this study add?
• Psoriasin expression is promoted by reactive oxygen species (ROS) and hypoxia in
keratinocytes. It regulates the ROS-induced expression of several psoriasis-associated
angiogenic factors, and acts on dermal endothelial cells to promote key features of
the angiogenic process.
What is the translational message?
• Our data raise the possibility that psoriasin may be evaluated as a novel antiangio-
genic target in psoriasis.
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Psoriasis is a chronic inflammatory skin disease characterized
by an intense hyperproliferation and a disturbed maturation of
keratinocytes, an inflammatory dermal infiltrate and the for-
mation of new blood vessels, in particular alterations of post-
capillary venules within the rete ridges.1–4
Microvascular modifications constitute one of the earliest
detectable changes in the development of the psoriatic
lesion.5,6 These modifications include dilatation, hyperperme-
ability, tortuosity and elongation of dermal blood vessels and
proliferation of endothelial cells.7 The vascular alterations in
psoriasis promote skin inflammation through the recruitment
of leucocytes to lesional skin.8 Several proangiogenic factors
are upregulated in the psoriatic epidermis. Vascular endothelial
growth factor (VEGF), a major epidermis-derived growth fac-
tor, is strongly upregulated in psoriatic skin,9 and is important
in the initiation of the psoriatic phenotype.10 Interestingly,
increased expression of VEGF is also present in nonlesional
skin.11 Transgenic mice overexpressing VEGF develop an
inflammatory skin disorder resembling psoriasis, with an
increased density of tortuous capillaries.12 Many of the
treatments used clinically, including tumour necrosis factor
(TNF)-a inhibitors, methotrexate and phototherapy, have
antiangiogenic properties.8 Despite this, the vascular contribu-
tion to the pathogenesis of psoriasis has generally received
limited attention. In fact, angiogenesis in psoriasis was recently
identified as a ‘research gap’ in the field of psoriasis.13
Psoriasin (S100A7) was originally identified as being highly
expressed in psoriatic lesions.14 It belongs to the S100 family
of calcium-binding proteins that are involved in several cellu-
lar processes, including proliferation, differentiation, invasion
and metastasis.15,16 An elevated expression of psoriasin has
been detected in some carcinomas of epithelial origin, such as
squamous cell carcinoma of the skin and bladder,17,18 as well
as in breast cancer, where its expression has been linked to
features of poor prognosis.19,20
In the skin, the expression of psoriasin is especially pro-
nounced in psoriasis; however, it is also elevated in other
hyperproliferative and inflammatory disorders.21 Psoriasin has
a distinct antimicrobial effect on Escherichia coli,14,22,23 and has
been shown to be chemotactic for CD4+ T cells and neu-
trophils.24 Psoriasin is induced by several proinflammatory
cytokines present in psoriatic skin, such as interleukin (IL)-1,
TNF-a, IL-17 and IL-22.25
The high expression of psoriasin in the psoriatic plaque,
along with its elevated expression in other conditions charac-
terized by angiogenesis, makes it a relevant protein to study
in the context of angiogenesis.
In this study, we aimed to identify the role of psoriasin in
psoriasis-associated angiogenesis.
Materials and methods
Cell culture conditions and treatments
Neonatal human epidermal keratinocytes (HEKn) were cul-
tured in Epilife medium (Cascade Biologics, Paisley, U.K.) as
previously described.26 Human embryonic kidney cells
(293FT; Invitrogen, Carlsbad, CA, U.S.A.) were grown in Dul-
becco’s modified Eagle’s medium (Gibco, Carlsbad, CA,
U.S.A.) supplemented with 10% fetal bovine serum (Gibco).
The immortalized, nontransformed keratinocyte cell line N/
TERT-2G was grown in keratinocyte serum-free medium
(Gibco) as previously described.27 Human dermal-derived
microvascular endothelial cells (HMVEC-d) were cultured in
endothelial basal medium supplemented with endothelial cell
growth medium-2 BulletKit (Lonza, Walkersville, MD, U.S.A.).
Recombinant human psoriasin was purchased from Abnova
(Taipei, Taiwan); VEGF was obtained from Invitrogen and the
IL-17 from R&D systems (Minneapolis, MN, U.S.A.). The inhi-
bitors LY294002 and caffeic acid phenethyl ester (CAPE) were
from Sigma Aldrich (St Louis, MO, U.S.A.).
Induction of cellular stress
To study the effect of stress conditions on psoriasin produc-
tion, HEKn were seeded at a density of 500 000 cells/T25
culture flask in complete Epilife medium. Following adher-
ence, the medium was replaced with fresh medium containing
150 or 250 lmol L1 H2O2 (Sigma Aldrich) for 24–48 h
(n = 4), or 500 lmol L1 CoCl2 (Sigma-Aldrich) for 24 h
(n = 4). To induce hypoxia (n = 6), the adhered cells were
given fresh medium and were subsequently moved to a
hypoxic chamber with 1% O2 where they remained for 24 h.
Following treatment, cells were harvested and lysed in RLT-
buffer (Qiagen, Hilden, Germany) for RNA extraction. Protein
quantification was performed nine times in H2O2-treated cells
and seven times in hypoxia-treated cells.
Small interfering RNA
Psoriasin small interfering RNA and a nontargeting siRNA
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, U.S.A.). HEKn were transfected with siRNA transfection
reagent and siRNA in Opti-MEM (Gibco). Cells were stimu-
lated with H2O2 24 h after transfection. The downregulation
of psoriasin was confirmed by quantitative real-time polymer-
ase chain reaction (qPCR). A total of six independent experi-
ments were performed.
RNA extraction, cDNA synthesis and quantitative real-
time polymerase chain reaction
RNA was prepared using the RNeasy mini kit (Qiagen) and
cDNA was synthesized using the Maxima First Strand cDNA
Synthesis Kit (Fermentas, Vilnius, Lithuania). mRNA expres-
sion was analysed with qPCR on a real-time 7500HT sequence
detection system with SYBR green detection (Applied Biosys-
tems, Foster City, CA, U.S.A.). The primers were as previously
described,28–32 or were designed using Primer Express Soft-
ware v3.0 (Applied Biosystems). All primer sequences are
listed in Table S1 (see Supporting Information). GAPDH or
RPLP0 were used as housekeeping genes. The relative
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expression of the target genes to untreated controls was deter-
mined using the comparative Ct method.
Cell proliferation and viability
Human dermal-derived microvascular endothelial cells were
seeded at 7500 cells per well in a 96-well plate and were
allowed to adhere before treatment. After adherence, the cell
culture medium was replaced with basal medium containing
either psoriasin (015 lg mL1 or 1 lg mL1) or VEGF
(10 ng mL1). Cells were allowed to proliferate for 24 h and
proliferation and viability were determined using a CellTiter
96 AQueous One Solution Cell proliferation assay [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium (MTS) (n = 5); Promega, Madison,
WI, U.S.A.] or PrestoBlue cell viability reagent (n = 4; Invitro-
gen), according to the manufacturer’s instructions. The results
were further verified in 12-well plates and by counting after
24, 48 and 72 h of treatment, which revealed a significant
increase in proliferation at 24 h but not at later time points
(data not shown). To examine whether VEGF mediated the
proliferative response, cells were treated with 02 lg mL1
VEGF-neutralizing antibody (R&D Systems), followed by treat-
ment with psoriasin or VEGF for 24 h. The absorbance was
recorded at the recommended wavelengths using the Versa-
Max Microplate Reader (Molecular Devices, Sunnyvale, CA,
U.S.A.). The relative absorbance was calculated for treated cells
vs. untreated cells.
Tube formation assay
The formation of HMVEC-d in capillary-like structures was
studied on Geltrex-reduced growth factor basement membrane
matrix (Invitrogen), according to the manufacturer’s instruc-
tions. Briefly, a total of 60 000 HMVEC-d cells were seeded
onto the matrix and were allowed to adhere. After adherence,
cells were treated with psoriasin (015 lg mL1 or 1 lg mL1;
Abnova) or VEGF (10 ng mL1). Tube formation was visual-
ized after 18 h of treatment using an Olympus IX51 inverted
microscope and an Olympus DP70 camera (Olympus, Tokyo,
Japan). Three independent experiments were performed. Tube
formation assays were quantified in ImageJ (National Institutes
of Health, Bethesda, MD, U.S.A.) with the macro Angiogenesis
Analyzer for ImageJ, detecting the total length, defined by the
sum of length of segments, isolated elements and branches. As
these experiments consisted of only three repeats, statistical
comparison of the quantifications was not deemed meaningful.
Scratch migration assay
The ability of psoriasin to mediate the migration of HMVEC-d
was evaluated in a scratch migration assay. Cells were seeded
densely in complete medium in 96-well plates and were
allowed to adhere. When the cells had adhered, the confluent
HMVEC-d monolayer was scratched with a pipette tip and
washed with phosphate-buffered saline to remove debris. The
medium was subsequently replaced with basal medium contain-
ing psoriasin (015 lg mL1 or 1 lg mL1) or IL-17
(50 ng mL1), used as a positive control as it is a key cytokine
in psoriasis. To inhibit the PI3K and nuclear factor kappa B
(NFjB) pathways, the inhibitors LY204002 (5 lmol L1) and
CAPE (50 lmol L1) were applied to the relevant wells 45 min
prior to psoriasin or IL-17 treatment. DMSO treatment was used
as diluent control. Cells were allowed to migrate in reduced
serum media containing treatment for 18 h. Migration of
HMVEC-d was visualized using an Olympus IX51 inverted
microscope and an Olympus DP70 camera. A total of three
independent experiments were performed. Scratch assays were
quantified in ImageJ using the detect edges feature and by mea-
suring the mean intensity in the area of the scratch. As these
experiments consisted of only three repeats, statistical compar-
ison of the quantifications was not deemed meaningful.
Directional cloning of the psoriasin sequence
Total RNA was extracted from homogenized human psoriatic
skin biopsies and cDNA synthesis was performed. Psoriasin
(NM_002963) was amplified by PCR with gene-specific pri-
mers. The forward primer included a short sequence at the 50-
end (CACC) for directional cloning into the pENTR/D-TOPO
vector (Invitrogen). After PCR amplification and gel purifica-
tion, the psoriasin DNA was cloned into pENTR followed by
transformation into One Shot TOP10 chemically competent
E. coli (Invitrogen). Insert DNA from positive clones was veri-
fied by DNA sequencing with M13 forward (50GTAAAA
CGACGGCCAG-30) and reverse (50-CAGGAAACAGCTATGAC-30)
primers.
Lentivirus-mediated gene expression
cDNA encoding the psoriasin gene was cloned into the lentivi-
ral expression vectors pLenti63/TO/V5-DEST and used to pro-
duce infectious lentivirus particles in 293FT cells, according to
the manufacturer’s instructions (Invitrogen). Keratinocytes
with constitutive psoriasin expression were generated by
infection of N/TERTs with the lentivirus constructs followed
by selection with 10 lg mL1 blasticidin. N/TERTs were
seeded at a density of 5000 cells per cm and grown to 40%
confluence. The medium was then replaced with new medium
that was harvested after 24, 48 and 72 h, and cells were lysed
with RLT buffer (Qiagen).
Enzyme-linked immunosorbent assay
The secreted levels of psoriasin, VEGF, matrix metalloproteinase
(MMP)-9 and IL-8 were quantitated using psoriasin/S100A7
(Circulex, Woburn, MA, U.S.A.), VEGF Quantikine (R&D Sys-
tems), MMP9 Quantikine (R&D Systems) or IL-8 Quantikine
(R&D Systems) ELISA kits, according to the manufacturer’s
instructions. ELISAs were performed on cell culture supernatant
or total protein extract. To obtain total protein, cells were lysed
in RIPA buffer (Thermo scientific, Rockford, IL, U.S.A.) and the
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protein level was measured with a Bio-Rad protein assay (Her-
cules, CA, U.S.A.). The protein was diluted in assay buffer
before the ELISA assay, to avoid RIPA interference. The absor-
bance of the assays was measured on a VersaMax Microplate
Reader (Molecular Devices) at the recommended wavelengths.
Gene expression microarray
RNA (100 ng) extracted from three psoriasin-expressing or
control N/TERTs (n = 3) after 24 h of culture was used to
generate hybridization probes using the GeneChip WT PLUS
Reagent kit (Affymetrix, Santa Clara, CA, U.S.A.), according to
the manufacturer’s instructions. Hybridization to GeneChip
human transcriptome 2.0 arrays was performed in a Gen-
eChip hybridization oven, followed by washing and staining
in a GeneChip Fluidics Station 450 and scanning in a Gen-
eChip Scanner 3000 7G system. Expression Console software
(version 1.2.1) was used to verify the quality controls. CEL-
files generated by the Affymetrix AGCC program were anal-
ysed with GeneSpring GX software (version 13.0; Agilent
Technologies, Santa Clara, CA, U.S.A.). A standard robust mul-
tiarray average normalization and background correction was
performed. The probe sets were filtered on expression with a
twentieth percentile cut-off. The fold change was computed
by the GeneSpring software as a ratio between the psoriasin-
overexpressing cells against the control cells. On the probe sets
that remained after the filtering, a 15-fold change was applied
as a cut-off for up- and downregulated genes. Heat maps of
the differentially regulated genes were constructed based on
normalized, filtered and log2-transformed data with Euclidean
similarity measure. Probe sets with a fold change ≥ 15 were
mapped on the gene ontology (GO) function, selecting for
‘regulators of angiogenesis’ and ‘positive regulators of angio-
genesis’ as biological functions.
Statistical analysis
Statistical analysis was performed in GraphPad Prism 6
(GraphPad Software, La Jolla, CA, U.S.A.), using a paired or
unpaired Student’s t-test and Wilcoxon’s signed rank test. A
value of P ≤ 005 was considered statistically significant. The
results are presented as mean  SD.
Results
Psoriasin expression is induced by cellular stress in
keratinocytes
Proangiogenic factors are triggered by stress signals, such as
oxidative stress and hypoxia. In psoriasis, the increased
production of reactive oxygen species (ROS) overrides the
effect of endogenous antioxidants.33 Treatment with H2O2
induced the expression of psoriasin in keratinocytes (Fig. 1a,
b), with the highest induction seen upon treatment with
250 lmol L1 H2O2 after 48 h. As expected, H2O2 also led to
the expression of VEGF (Figs 2b and 1c).
Hypoxia has been shown to induce the production of
ROS,34 and a hypoxic state has been suggested in the psoriatic
plaque.35 We therefore cultured HEKn in a hypoxic chamber
with 1% O2 for 24 h. This culture significantly induced the
expression of psoriasin (Fig. 1d,f), as well as the expression
of VEGF, which functioned as a positive control (Fig. 1e,g).
Similarly, the hypoxia-mimicking agent, CoCl2, induced both
psoriasin (Fig. 1h) and VEGF expression (Fig. 1i). Our data
demonstrate that the oxidative stress factors H2O2, hypoxia
and CoCl2 all induce psoriasin expression in keratinocytes.
Psoriasin mediates H2O2-induced expression of psoriasis-
associated angiogenic factors in keratinocytes
To determine whether psoriasis-associated factors of angiogen-
esis are affected by the expression of psoriasin, the levels of
these factors were measured after treating keratinocytes with
H2O2. In addition to giving rise to induced psoriasin expres-
sion (Fig. 2a), this treatment also increased the levels of the
proangiogenic factors VEGF (Fig. 2b), heparin-binding epider-
mal growth factor-like growth factor (HB-EGF; Fig. 2c),
MMP-1 (Fig. 2d), MMP-9 (Fig. 2e) and IL-8 (Fig. 2f),
whereas the expression of the antiangiogenic factor throm-
bospondin (THBS)-1 (Fig. 2g) was reduced. To investigate the
specific effect of psoriasin in the H2O2-promoted induction of
these factors, we downregulated the endogenous expression of
psoriasin using siRNA. The efficient downregulation of psori-
asin was confirmed by qPCR (Fig. 2a). The expression of the
proangiogenic factors VEGF (Fig. 2b), HB-EGF (Fig. 2c) and
MMP-1 (Fig. 2d) was found to be significantly decreased in
cells with downregulated psoriasin expression, suggesting that
psoriasin participates in their regulation. The expression of
MMP-9 (Fig. 2e) and IL-8 (Fig. 2f) was decreased without
reaching statistical significance. Furthermore, the expression of
the antiangiogenic factor THBS-1 was significantly increased in
cells with downregulated psoriasin expression. These results
suggest that psoriasin amplifies the angiogenic response to
H2O2 in keratinocytes.
Psoriasin does not influence angiogenic markers by
upregulating vascular endothelial growth factor receptors
We speculated that psoriasin might influence these angiogenic
factors through the induction of the VEGF receptors R1 and
R2, as many of these markers are targets of VEGF. Treatment
with extracellular psoriasin did not induce the mRNA expres-
sion of VEGFR1 and VEGFR2 in keratinocytes, nor did the
treatment synergize with VEGF to upregulate these receptors
(data not shown).
Overexpression of psoriasin leads to secretion of
psoriasin into the extracellular space and altered
expression of general regulators of angiogenesis
To further determine the effect of psoriasin on angiogenesis
and the potential of the protein to influence surrounding cells,
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we generated keratinocytes with constitutively overexpressed
psoriasin. The efficient upregulation of psoriasin expression
was confirmed with qPCR (data not shown) and with a psori-
asin ELISA, which revealed a pronounced psoriasin expression
at all the investigated time points (Fig. 2h). These results
demonstrate not only the successful overexpression of psori-
asin in the generated cells, but also that psoriasin protein is





















































































































































































































































































































Fig 1. Psoriasin is induced by angiogenesis-
promoting stress stimuli in keratinocytes.
Neonatal human epidermal keratinocytes
(HEKn) were either treated with H2O2 (150–
250 lmol L1) for 48 h, cultured in hypoxia
or treated with the hypoxia-mimicking agent
CoCl2 (500 lmol L
1), for 24 h. The
expression of psoriasin and vascular
endothelial growth factor (VEGF) was
analysed using quantitative real-time
polymerase chain reaction. (a) H2O2
treatment increased psoriasin mRNA
expression compared with untreated cells
(n = 4), as well as the expression of both (b)
psoriasin (n = 9) and (c) VEGF protein
(n = 9). Furthermore, culture in hypoxia
increased psoriasin at both the (d) mRNA
(n = 6) and (f) protein (n = 7) level. Hypoxia
also successfully induced the (e) mRNA
(n = 6) and (g) protein (n = 7) of the
positive control, VEGF. The treatment of
HEKn with CoCl2 induced the expression of
(h) psoriasin and the expression of (i) VEGF
(n = 4). Gene expression levels are shown as
the relative fold induction vs. untreated
controls. (a) GAPDH or (d, e, h, i) RPLP0 were
used as reference genes. Psoriasin protein
expression is measured as ng per mg of total
protein and VEGF as pg per mg of total
protein. Data are presented as mean  SD.
*P < 005 and **P < 001. ns, nonsignificant.
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Fig 2. The downregulation of psoriasin
expression in H2O2-treated keratinocytes
regulates the expression of angiogenic factors.
Neonatal human epidermal keratinocytes
(HEKn) were transfected with small
interfering (siRNA) directed against psoriasin
(Pso-siRNA) or negative control siRNA (C-
siRNA), and were treated with 250 lmol L1
H2O2 for 48 h. Expression was analysed by
quantitative polymerase chain reaction. (a)
The downregulation of psoriasin was
confirmed in H2O2-treated HEKn. The
downregulation of psoriasin suppressed the
H2O2-induced mRNA expression of (b)
vascular endothelial growth factor (VEGF), (c)
heparin-binding epidermal growth factor-like
growth factor (HB-EGF), (d) matrix
metalloproteinase (MMP)-1, (e) MMP-9 and
(f) IL-8, and (g) increased the mRNA
expression of thrombospondin (THBS)-1.
mRNA expression is normalized to GAPDH.
The results are shown as the relative
expression of treated cells in relation to
untreated cells (n = 6). To study the effect of
psoriasin on general regulators of
angiogenesis, keratinocytes overexpressing
psoriasin were generated. The generated
keratinocytes (ps-NTERT) secreted markedly
higher levels of (h) psoriasin than the control
cells at all investigated time points (n = 3)
and (i) a higher level of MMP-9 (ng mL1)
after 48 h (n = 3). Data are expressed as
mean  SD. *P < 005, **P < 001,
***P < 0001. ns, nonsignificant.
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overexpression of psoriasin was accompanied by an upregula-
tion of MMP-9 (Fig. 2i).
To determine the effect of this overexpression on angio-
genic factors, we performed a microarray expression analysis
where we searched for general regulators of angiogenesis. A
total of 56 372 probe sets were above the twentieth percentile
of expression on all arrays and were further analysed. Of
these, 283 probe sets had a fold change of ≥ 15 in the com-
parison between cells with upregulated psoriasin and control
cells.
The overexpression of psoriasin induced the upregulation of
several factors which by the GO pathways were associated
with the regulation of angiogenesis, including the comple-
ment component 3, IL-1a, IL-1b, MMP-9, coagulation factor
3, THBS-1 and TNF-a-induced protein 3. The GO pathways
also identified the downregulated gene KRT1 as a regulator of
angiogenesis (Fig. S1; see Supporting Information).
Furthermore, several factors that have been suggested to
regulate angiogenesis were altered, including MMP-10, plas-
minogen activator urokinase and transforming growth factor-
b2 (Table S2; see Supporting Information), which suggests
that psoriasin affects a broad range of general regulators of
angiogenesis.
Psoriasin induces cell proliferation, migration and
capillary-like tube formation in dermal endothelial cells
Key steps in the angiogenic process involve endothelial cell
proliferation, migration through the extracellular matrix and
the differentiation of endothelial cells into a network of tubes.
In order to study the effect of secreted psoriasin on these
steps, HMVEC-d were treated with psoriasin and investigated
using an MTS and a Presto Blue viability assay to determine
proliferation, a scratch assay to study migration and a tube
network formation assay to evaluate angiogenic capacity.
Extracellular psoriasin induced the proliferation of the
endothelial cells, as determined by the MTS assay (Fig. 3a)
and the Presto Blue viability assay (Fig. 3b). This effect was
found to be independent of VEGF as VEGF-neutralizing anti-
body did not abolish the proliferation (Fig. 3c). Psoriasin
also caused a pronounced cellular migration of HMVEC-d
(Fig. 3d), comparable with that induced by the positive con-
trol, VEGF. Furthermore, psoriasin triggered the formation of
tube networks and generated more cell connections on Gel-
trex matrix than the basal medium control (Fig. 3e). In con-
clusion, our results demonstrate that extracellular psoriasin
increases the angiogenic properties of dermal endothelial
cells, to an extent comparable with that of extracellular
VEGF.
Psoriasin-induced dermal-derived endothelial cell
migration is mediated through the PI3K and nuclear
factor kappa B pathways
Vascular endothelial growth factor and IL-17 activate the PI3K
and NFjB signalling pathways in endothelial cells and regulate
downstream target molecules involved in blood vessel growth
and homeostasis.36,37 To investigate whether these signalling
pathways also underlie psoriasin-induced HMVEC-d migration,
we examined the effect of inhibitors of PI3K (LY294002) or
NFjB (CAPE) following treatment with psoriasin or IL-17. IL-
17 was shown to stimulate HMVEC-d migration and was also
used as the positive control (Fig. 3f). The promoting effect of
psoriasin on HMVEC-d migration was effectively blocked by
the inhibition of the PI3K (Fig. 3g) and NFjB (Fig. 3h) path-
ways. LY294002 and CAPE alone had no effect on HMVEC-d
migration, nor did dimethyl sulfoxide, used as a diluent
control.
Psoriasin induces the expression of angiogenic factors in
dermal endothelial cells
To acquire further insights into the mechanisms by which
psoriasin increases angiogenesis, we analysed intracellular
angiogenic factors in HMVEC-d cells in response to extracellu-
lar psoriasin. We demonstrated a significant increase in the
mRNA expression of the proangiogenic factors VEGF (Fig. 4a)
and IL-8 (Fig. 4b). Although not statistically significant, we
observed an increase in MMP-1 (Fig. 4c) and IL-6 (Fig. 4d)
expression. The expression of the antiangiogenic factor THBS-
1 was found to be reduced by treatment with psoriasin
(Fig. 4e). In addition, treatment with psoriasin upregulated
the expression of the psoriasin receptor RAGE (receptor for
advanced glycation endproducts), suggesting that psoriasin
exposure might further potentiate cell reactivity to the protein
(Fig. 4f).
Furthermore, IL-8 protein secretion from the HMVEC-d
cells was increased after psoriasin treatment, as demonstrated
by ELISA (Fig. 4g). Extracellular psoriasin thus induces the
expression and release of proangiogenic cytokines in dermal
endothelial cells.
Discussion
Reactive oxygen species play an important role in signal trans-
duction and induce the transcription of cytokines, chemokines
and growth factors, which participate in many biological pro-
cesses, including angiogenesis.38 We have previously shown
that psoriasin is induced by H2O2 in mammary epithelial cells
and induces human umbilical vein endothelial cell prolifera-
tion.32,39 We have also demonstrated that the downregulation
of psoriasin in a breast cancer cell line with a high endoge-
nous expression of psoriasin led to decreased tumour growth
in vivo.28 In line with these findings, we also found the upreg-
ulation of MMP-13 and the downregulation of VEGF in cells
with reduced psoriasin levels. Moreover, we observed a signif-
icant positive correlation between psoriasin expression and
blood vessel density, determined by the immunohistochemical
analysis of psoriasin and CD31, an endothelial cell-specific
marker.28
In this study, we detected the upregulation of psoriasin by
cellular stress (H2O2 and hypoxia) in keratinocytes.
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Furthermore, we demonstrate that psoriasin regulates the
expression of the psoriasis-associated angiogenic factors VEGF,
HB-EGF, IL-8, MMP-1 and MMP-9 in H2O2-treated
keratinocytes, as indicated by the diminished response to ROS
when psoriasin is silenced with siRNA. We have previously


















































































Control VEGF 10 ng mL–1
Psoriasin 0·15 μg mL–1 Psoriasin 1·0 μg mL–1 Psoriasin 1·0 μg mL–1 Psoriasin 10 μg mL–1










































































































































































Control IL-17 50 ng mL–1
Pso 1·0 μg mL–1Pso 0·15 μg mL–1
DMSO
DMSO CAPE 50 μmol L–1 CAPE + IL -17 CAPE + Pso 0·15 μg mL–1 CAPE + Pso 1·0 μg mL–1













































































































































Fig 3. Psoriasin induces cell proliferation, migration and the capillary-like tube formation of dermal-derived endothelial cells. Human dermal-
derived microvascular endothelial cells (HMVEC-d) were treated with psoriasin (015–100 lg mL1) or vascular endothelial growth factor (VEGF;
10 ng mL1) for 24 h. The quantity of viable cells in proliferation was measured by (a) the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (n = 5) or (b) the PrestoBlue cell viability reagent (n = 4). (c) Treatment
with VEGF-neutralizing antibody (02 lg mL1) did not abolish the psoriasin-induced proliferation, measured by PrestoBlue (n = 7). The results are
presented as the relative absorbance of the treated cells in relation to the untreated cells. The bar represents the mean  SD (*P < 005, **P < 001).
(d) In a subsequent experiment, HMVEC-d were grown to confluence and scratched, followed by treatment with psoriasin (015–10 lg mL1) or
VEGF (10 ng mL1) (n = 3). (e) HMVEC-d cells were also seeded onto Geltrex and treated with psoriasin or VEGF for 18 h and capillary-like tube
formation was photographed (n = 3). Basal medium served as a negative control, while VEGF and complete medium were used as positive controls.
To investigate the pathways involved in the psoriasin-induced cell migration, HMVEC-d were grown to confluence, scratched and pretreated with
LY204002 (5 lmol L1) or caffeic acid phenethyl ester (CAPE; 50 lmol L1) for 45 min followed by stimulation with psoriasin or the positive
control interleukin (IL)-17 (50 ng mL1) for 18 h. (f) Psoriasin and IL-17 induced HMVEC-d migration. The (g) PI3K-inhibitor, LY204002, and
the (h) nuclear factor kappa B inhibitor, CAPE, prevented psoriasin-induced migration. Neither LY294002 and CAPE alone nor dimethyl sulfoxide
(used as a diluent control) had any effect on HMVEC-d migration. The photographs are representative examples of three individual experiments. Bar
graphs display the mean  SD and the migration or total length of tube formation relative to the control. ns, nonsignificant.
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ROS in keratinocytes, suggesting a feedback loop where psori-
asin is both induced by ROS and amplifies the angiogenic
response to ROS.29
Among the factors that were regulated by psoriasin, VEGF is
of particular interest because of its overexpression in psoriatic
keratinocytes and its potent mitogenic effect on endothelial
cells.6,40 Extracellular psoriasin also induced the expression of
VEGF and IL-8 in dermal endothelial cells, in parallel with an
induced cell proliferation. Furthermore, extracellular psoriasin
also caused an increase in the expression of the RAGE
receptor. As psoriasin is known to be a ligand of RAGE,41 this
suggests that the upregulation of this receptor upon psoriasin
treatment may potentiate the response to psoriasin in an auto-
crine fashion.
The regulation of MMPs by psoriasin is also of interest as they
are involved in the proteolysis of the basement membrane,
which is a critical step during the very early stages of angiogene-
sis.42 Similarly, HB-EGF, which is upregulated in the psoriatic
lesion,43 is a critical molecular component in wound healing
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Fig 4. Psoriasin induces the expression of
angiogenic factors in dermal endothelial cells.
Human dermal-derived microvascular
endothelial cells (HMVEC-d) were treated
with psoriasin (015–10 lg mL1) for 24 h.
Expression was analysed by real-time
quantitative polymerase chain reaction.
Psoriasin treatment induced the mRNA
expression of (a) vascular endothelial growth
factor (VEGF; n = 8), (b) interleukin (IL)-8
(n = 8), (c) matrix metalloproteinase (MMP)-
1 (n = 3) and (d) interleukin (IL)-6 (n = 8),
while (e) reducing the mRNA expression of
thrombospondin 1 (n = 6). (f) Furthermore,
the expression of the psoriasin receptor RAGE
(receptor for advanced glycation endproducts)
was upregulated upon treatment (n = 6). (g)
Treatment with psoriasin also caused the
production of IL-8, measured by enzyme-
linked immunosorbent assay of cell
supernatant (n = 7). VEGF (10 ng mL1) was
used as the positive control. The results are
shown as the relative expression of treated
cells in relation to untreated cells. The mRNA
expression is normalized to GAPDH as the
internal control. Data are expressed as
mean  SD. *P < 005, **P < 001. ns,
nonsignificant.
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H2O2-treated keratinocytes with silenced psoriasin expression is
in line with previous findings where we have observed a nega-
tive correlation between psoriasin and THBS-1 in normal and
ductal carcinoma in situ specimens.45 The microarray analysis of
keratinocytes overexpressing psoriasin also suggests that psori-
asin affects a broad range of angiogenic factors. We found that
psoriasin is highly secreted and leads to the proliferation, migra-
tion and differentiation of dermal endothelial cells.
In conclusion, our findings demonstrate that psoriasin
amplifies the stress-induced angiogenic response in ker-
atinocytes and endothelial cells and is involved in potent
proangiogenic activity in several crucial steps in the angio-
genic process in vitro. These findings provide a link between
psoriasin and angiogenesis, and suggest that the high expres-
sion of psoriasin contributes to the increased vascularization in
psoriatic epidermis and the progression of the disease. Our
findings raise the possibility that psoriasin could be evaluated
as a novel antiangiogenic target in psoriasis.
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